HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

HC Wainwright restated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com raised shares of Lexicon Pharmaceuticals to a “sell” rating in a research note on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.50.

Lexicon Pharmaceuticals Stock Up 5.2 %

NASDAQ LXRX opened at $2.01 on Thursday. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.73. The company has a quick ratio of 11.49, a current ratio of 11.51 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $494.94 million, a P/E ratio of -2.42 and a beta of 1.28. The stock’s 50-day moving average price is $1.68 and its 200-day moving average price is $1.78.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $2.74 million. Lexicon Pharmaceuticals had a negative return on equity of 105.38% and a negative net margin of 5,509.34%. During the same period in the prior year, the company posted ($0.22) EPS. On average, equities research analysts predict that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its stake in shares of Lexicon Pharmaceuticals by 82.6% during the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 26,859 shares during the period. Vanguard Group Inc. increased its holdings in Lexicon Pharmaceuticals by 7.0% in the first quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock valued at $15,363,000 after buying an additional 420,854 shares in the last quarter. Boulder Hill Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals in the first quarter worth about $615,000. Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth about $105,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $912,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.